var data={"title":"Effect of herpes simplex virus on HIV infection: Implications for HIV prevention","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Effect of herpes simplex virus on HIV infection: Implications for HIV prevention</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/contributors\" class=\"contributor contributor_credentials\">Christine Johnston, MD, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/contributors\" class=\"contributor contributor_credentials\">Anna Wald, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 07, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H4510284\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Herpes simplex virus type 2 (HSV-2) infection is highly prevalent among HIV-infected patients. Whether this association results from similar modes of acquisition or to biologic interactions between the two viruses has been a topic of intense debate.</p><p>This topic will address interactions between HIV and HSV-2 and the implications for HIV prevention. The natural history, clinical manifestations, diagnosis, and treatment of genital HSV infection in the HIV-infected host are discussed elsewhere. (See <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-type-2-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus type 2 in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H346164\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The discussion below addresses the effect of HSV-2 infection on HIV acquisition and transmission.</p><p class=\"headingAnchor\" id=\"H2188350\"><span class=\"h2\">HIV acquisition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several lines of evidence suggest that prevalent and incident HSV-2 infections increase the risk of HIV acquisition.</p><p class=\"headingAnchor\" id=\"H346025\"><span class=\"h3\">Prevalent HSV-2 infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Epidemiologic studies have shown that HSV-2-seropositive persons have a two- to threefold increased risk of acquiring HIV infection compared with HSV-2-seronegative persons [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/1-5\" class=\"abstract_t\">1-5</a>]. </p><p>Mathematical models estimate that in settings of high HSV-2 prevalence, more than 25 percent of incident HIV infections may be attributed to HSV-2 infection [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/6\" class=\"abstract_t\">6</a>]. Observational epidemiologic studies support similar findings: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a meta-analysis of 18 longitudinal studies, HSV-2 infection was associated with 2.7-fold increased risk of HIV acquisition among men (95% CI 1.9-3.9), and a 3.1-fold increased risk among women (95% CI 1.7-5.6), after adjusting for age and sexual behavior [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/3\" class=\"abstract_t\">3</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another meta-analysis of 31 case-control, cohort, and cross-sectional studies, the attributable risk of HIV infection related to HSV-2 ranged from 19 percent where HSV-2 seroprevalence was roughly 20 percent (eg, the United States) to 47 percent where HSV-2 seroprevalence exceeded 80 percent (eg, female sex workers in sub-Saharan Africa) [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/4\" class=\"abstract_t\">4</a>]. </p><p/><p class=\"headingAnchor\" id=\"H4510298\"><span class=\"h3\">Incident HSV-2 infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Incident HSV-2 infection is associated with an even greater risk for HIV acquisition than prevalent HSV-2 [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/7-15\" class=\"abstract_t\">7-15</a>]. This observation may be related to the greater number of clinical and subclinical reactivation episodes, which occur within the first year of HSV-2 acquisition [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/16-18\" class=\"abstract_t\">16-18</a>]. Alternatively, incident HSV-2 and HIV infections may simply be epidemiologic markers for having a sex partner with both infections.</p><p class=\"headingAnchor\" id=\"H2188381\"><span class=\"h2\">HIV transmission</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HSV infection also increases the risk of HIV transmission. </p><p class=\"headingAnchor\" id=\"H2188414\"><span class=\"h3\">Discordant couples</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &ldquo;HIV discordant couples&rdquo; is used to describe two sex partners who differ according to their HIV infection status. Carefully performed studies among HIV discordant couples have demonstrated that HSV-2 infection in the source partner increases the probability of HIV transmission by nearly fivefold per coital act compared with those HIV-infected sex partners who are HSV-2-seronegative [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/19\" class=\"abstract_t\">19</a>].</p><p class=\"headingAnchor\" id=\"H346171\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several biologic mechanisms have been proposed to explain the observation that HSV-2 infection may increase the risk of HIV acquisition and transmission, as discussed below. </p><p class=\"headingAnchor\" id=\"H346053\"><span class=\"h2\">Disruption of mucous membranes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sexually transmitted diseases (STDs), both bacterial and viral, are linked to an increased risk of HIV acquisition [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/20\" class=\"abstract_t\">20</a>]. Genital ulcerative diseases, such as that caused by HSV-2, lead to disruption of skin or mucous membranes with the formation of microscopic and macroscopic ulcers, which may enhance HIV acquisition by providing direct access to potential target cells [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/21\" class=\"abstract_t\">21</a>]. However, HSV-2 serostatus alone is associated with an increased risk of HIV acquisition, independent of the presence of genital ulcers or HSV-2 shedding, suggesting that other factors may play a role [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H346082\"><span class=\"h2\">Local immunologic factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Substantial evidence demonstrates that HSV-2: a) enhances susceptibility to HIV infection among those who are HIV-seronegative and b) increases the risk of HIV transmission from those who are chronically infected with HIV [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/22,23\" class=\"abstract_t\">22,23</a>]. Local inflammatory changes in the genital tract may explain these phenomena:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Compared with those without HSV-2 infection, HIV-infected patients with HSV-2 infection have enrichment of HSV-2-specific CD4+ and CD8+ T cells and other inflammatory cells in genital secretions [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/22,24\" class=\"abstract_t\">22,24</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In HSV-seropositive patients who are HIV-uninfected, increased numbers of cellular targets of HIV (eg, CD4+ and CD8+ T cells and dendritic cells) with the necessary coreceptors for cellular entry (eg, CCR5) have been demonstrated in the female cervix, the male foreskin, and in tissue from healed genital ulcers months after HSV-2 reactivation [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/22,23,25\" class=\"abstract_t\">22,23,25</a>].</p><p/><p class=\"headingAnchor\" id=\"H2188488\"><span class=\"h2\">HIV RNA shedding in HSV genital lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Increased HIV RNA shedding among male and female patients with HSV infection may be an important factor contributing to HIV transmission [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/24,26\" class=\"abstract_t\">24,26</a>]. For example, studies of women from Kenya, Ghana, the Central African Republic, and Burkina Faso demonstrated that cervicovaginal HIV RNA was detected more frequently, and at higher copy number, in the genital tract of HSV-2-seropositive women with HSV-2-associated ulcers or viral shedding, compared with women without HSV-2 infection [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/27,28\" class=\"abstract_t\">27,28</a>]. </p><p class=\"headingAnchor\" id=\"H5754473\"><span class=\"h1\">HSV THERAPY AND HIV ACQUISITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The epidemiologic data discussed above raise the question as to whether antiviral therapy for HSV-2 infection can reduce HIV acquisition among HIV-seronegative persons. However, two randomized, double-blind, placebo-controlled trials in high-risk HSV-2-positive, HIV-negative women in Tanzania [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/29\" class=\"abstract_t\">29</a>] and men who have sex with men (MSM) in North and South America and women in sub-Saharan Africa [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/30\" class=\"abstract_t\">30</a>], showed that <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> (400 mg twice daily) does not prevent HIV acquisition among HSV-2-seropositive individuals.</p><p class=\"headingAnchor\" id=\"H347552\"><span class=\"h1\">HSV THERAPY AND HIV TRANSMISSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The observed epidemiologic trends and studies of pathogenesis raise three basic questions. Can viral suppression of HSV-2 with antiviral therapy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lower levels of plasma HIV viremia?</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decrease HIV genital shedding?</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduce rates of HIV transmission?</p><p/><p class=\"headingAnchor\" id=\"H275545\"><span class=\"h2\">Effect of HSV treatment on HIV replication</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of HSV-2-related genital ulcerative disease can include either: a) chronic suppressive therapy or b) episodic therapy for genital ulcers as they occur. Both approaches have been evaluated for their potential effect on HIV replication and genital HIV shedding. (See <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-type-2-in-hiv-infected-patients#H251515427\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus type 2 in HIV-infected patients&quot;, section on 'Treatment strategies for recurrent disease'</a>.)</p><p>Clinical trials have shown that daily antiviral therapy for suppression of genital HSV-2 is associated with a decline in plasma HIV viremia [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/31-42\" class=\"abstract_t\">31-42</a>]. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> (500 mg twice daily) was associated with a sustained 0.3 to 0.5 log<sub>10</sub> decrease in HIV plasma RNA levels over three months of follow-up among <span class=\"nowrap\">HIV/HSV-2-coinfected</span> women who were not taking antiretroviral therapy (ART) [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/32,33\" class=\"abstract_t\">32,33</a>]. In studies with up to 24 months of follow-up, similar findings have been observed with <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> among HIV-infected men and women who were coinfected with HSV-2 [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/31,34,35\" class=\"abstract_t\">31,34,35</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a comparative trial of 32 <span class=\"nowrap\">HIV/HSV-2</span> coinfected individuals from Kenya who were not on ART, high-dose <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (1500 mg twice daily) was associated with a 0.6 log<sub>10</sub> <span class=\"nowrap\">copy/mL</span> greater decline in HIV RNA levels compared with standard dose <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> (400 mg twice daily) [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/41\" class=\"abstract_t\">41</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a similar study of 34 <span class=\"nowrap\">HIV/HSV-2</span> coinfected individuals not on ART from the United States, <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (1 gm twice daily) was associated with 0.3 log10 <span class=\"nowrap\">copies/ml</span> greater decline in HIV RNA as compared with standard dose <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> (400 mg twice daily) [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/42\" class=\"abstract_t\">42</a>]. </p><p/><p>The mechanisms that may account for declines of plasma HIV RNA during therapy for HSV-2 infection are unclear. In vitro studies have shown that high, but clinically relevant concentrations of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> may have inhibitory effects against HIV replication [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/43\" class=\"abstract_t\">43</a>], and drug exposure leads to emergence of certain mutations within HIV reverse transcriptase [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/44,45\" class=\"abstract_t\">44,45</a>]. Whether acyclovir directly inhibits HIV replication in vivo at physiologic doses is uncertain, since these particular mutations have not been seen among acyclovir-exposed patients, even after prolonged duration of daily therapy [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/46,47\" class=\"abstract_t\">46,47</a>]. Alternatively, the reduction in plasma HIV RNA may be mediated by reduced inflammation secondary to HSV suppression, which could lead to a lower number of target cells for HIV.</p><p class=\"headingAnchor\" id=\"H2190093\"><span class=\"h2\">Effect of HSV therapy on HIV genital shedding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The effect of HSV antiviral therapy on HIV genital shedding is less clear. Although daily use of <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (500 mg twice daily) has been associated with a decline in frequency and quantity of HIV shedding in <span class=\"nowrap\">HIV/HSV-2-coinfected</span> men and women [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/33,36,37\" class=\"abstract_t\">33,36,37</a>], trials assessing the effect of suppressive therapy with <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> have had inconsistent findings [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/34,35,48\" class=\"abstract_t\">34,35,48</a>]. Furthermore, episodic acyclovir therapy (400 mg three times daily for five days) for recurrent HSV-2 disease reduced the frequency and quantity of HIV genital shedding among men with genital ulcers [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/49\" class=\"abstract_t\">49</a>], but had no effect on HIV genital shedding among women [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/50\" class=\"abstract_t\">50</a>].</p><p class=\"headingAnchor\" id=\"H2540913\"><span class=\"h2\">HSV suppression and risk of HIV transmission</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Despite the overwhelming epidemiologic and biologic evidence for an association between HSV-2 infection and HIV infection, HSV-2 suppressive therapy does not appear to decrease the risk of HIV transmission [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/31\" class=\"abstract_t\">31</a>]. A controlled trial (Partners in Prevention <span class=\"nowrap\">HSV/HIV</span> Transmission Study) was conducted in 14 sites in Africa to evaluate whether suppressive antiviral therapy with <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> would reduce HIV transmission among 3408 HIV discordant heterosexual couples [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/31\" class=\"abstract_t\">31</a>]. <span class=\"nowrap\">HIV/HSV-coinfected</span> partners were randomly assigned to acyclovir (400 mg twice daily) or placebo. All eligible patients had a CD4 count &gt;250 <span class=\"nowrap\">cells/microL</span> and thus did not meet national guidelines for ART at the time the study was performed. The following summary illustrates the main findings [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/31\" class=\"abstract_t\">31</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> reduced the occurrence of genital ulcers by 73 percent and reduced HIV RNA levels by 0.25 log<sub>10</sub> <span class=\"nowrap\">copies/mL</span> in the <span class=\"nowrap\">HIV/HSV-coinfected</span> partners. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>However, the numbers of HIV transmission events that were linked (as determined by viral sequencing) were similar in the intervention and placebo arms. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No serious adverse events were observed.</p><p/><p class=\"headingAnchor\" id=\"H2189330\"><span class=\"h1\">THE IMPACT OF HSV-2 INFECTION ON HIV DISEASE</span></p><p class=\"headingAnchor\" id=\"H2189567\"><span class=\"h2\">Impact of HSV-2 on plasma HIV RNA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several studies have shown that HSV-2 infection is associated with increased levels of plasma HIV RNA among HIV-1 chronically-infected patients [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/27,51,52\" class=\"abstract_t\">27,51,52</a>]. In a small study of HIV-infected patients with a history of recurrent HSV-2 genital ulcers, an acute outbreak of genital ulcers was associated with a 3.4-fold rise in plasma HIV RNA that persisted above baseline levels for more than one month [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/51\" class=\"abstract_t\">51</a>]. In contrast, levels of HIV RNA declined with initiation of HSV antiviral therapy [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/52\" class=\"abstract_t\">52</a>].</p><p>However, there are conflicting data as to whether HSV-2 infection is associated with increased plasma HIV RNA among patients with acute HIV infection [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/53-55\" class=\"abstract_t\">53-55</a>]. </p><p class=\"headingAnchor\" id=\"H2189594\"><span class=\"h3\">Mechanisms of enhanced HIV replication</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In vitro studies have highlighted potential mechanisms through which HSV may promote HIV replication in chronically infected patients: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HSV-2 can activate HIV from an inactive (latent) state [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/56,57\" class=\"abstract_t\">56,57</a>]. HSV upregulates cellular proteins, which are associated with transcriptional activation of HIV-1 [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/24,56-61\" class=\"abstract_t\">24,56-61</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Within CD4+ T cells, HSV-2 upregulates HIV replication and gene expression [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/24,60\" class=\"abstract_t\">24,60</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HSV-2 genital ulcers demonstrate an influx of HSV-specific CD8+ T-cells, which contribute to HSV-2 clearance [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/62\" class=\"abstract_t\">62</a>]. These cells persist and accumulate in the dermal skin [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/63\" class=\"abstract_t\">63</a>] and may contribute to local immune activation [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/64\" class=\"abstract_t\">64</a>], which is associated with elevated levels of proinflammatory cytokines. These changes may be associated with CD4 cell decline [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/65\" class=\"abstract_t\">65</a>].</p><p/><p class=\"headingAnchor\" id=\"H2189227\"><span class=\"h2\">Impact of HSV-2 on T cell decline and recovery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The impact of HSV-2 infection on CD4 cells has been examined. The observational data discussed below do not suggest a major effect of HSV-2 coinfection on CD4 cell trajectories [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/55,66\" class=\"abstract_t\">55,66</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One study evaluated the impact of HSV-2 status on the immunologic status and plasma HIV RNA among 186 HIV seroconverters [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/55\" class=\"abstract_t\">55</a>]. No relationship between HSV-2 serostatus and plasma HIV-1 RNA levels were seen. In addition, persons with <span class=\"nowrap\">HIV-1/HSV-2</span> coinfection had significantly higher CD4 cell counts compared with those with HIV-1 infection alone, after adjustment for HIV-1 RNA levels. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an observational study of 1938 chronically HIV-infected women with HSV-2 infection, there was a modest relationship between the frequency of HSV reactivation episodes and CD4 cell loss [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/67\" class=\"abstract_t\">67</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another observational study compared rates of CD4 cell count decline by HSV-2 status in 218 HIV-infected adults who were not receiving antiretroviral (ART) or anti-HSV therapy and had a baseline CD4 count &ge;400 <span class=\"nowrap\">cells/microL</span>. HSV-2 infection was not associated with a higher rate of CD4 cell decline, but was significantly associated with an earlier combined endpoint of ART initiation or CD4 count &lt;350 <span class=\"nowrap\">cells/microL</span> (hazard ratio [HR] 2.07, 95% CI 1.28-3.33) [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/68\" class=\"abstract_t\">68</a>].</p><p/><p class=\"headingAnchor\" id=\"H2541616\"><span class=\"h2\">HSV-2 antiviral therapy and HIV progression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A 1998 meta-analysis of clinical trials performed prior to the widespread availability of potent ART found that high-dose <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> (&ge;3200 <span class=\"nowrap\">mg/day)</span> was associated with reduced overall mortality (HR 0.78, 95% CI 0.65-0.93) [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/69\" class=\"abstract_t\">69</a>].</p><p class=\"headingAnchor\" id=\"H347860494\"><span class=\"h2\">Individuals not receiving antiretroviral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The effect of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> administration (400 mg twice daily) on HIV disease progression was investigated in a placebo-controlled clinical trial of 440 <span class=\"nowrap\">HIV/HSV-2</span> dually-infected treatment-na&iuml;ve adults with CD4 counts ranging between 300 and 400 <span class=\"nowrap\">cells/microL</span> [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/70\" class=\"abstract_t\">70</a>]. The primary outcome was a CD4 count &lt;250 <span class=\"nowrap\">cells/microL</span> or the initiation of ART for WHO stage 4 disease (eg, presence of HIV wasting or an opportunistic infection). The trial demonstrated that patients with a baseline plasma viral load &gt;50,000 <span class=\"nowrap\">copies/mL</span> who were assigned acyclovir had a significant reduction in HIV clinical progression compared with those assigned placebo (HR 0.62, 95% CI 0.43-0.96), whereas no benefit was seen among those with lower levels of HIV RNA (0.90, 95% CI 0.54-1.5). </p><p>In a randomized trial of 148 <span class=\"nowrap\">HIV/HSV-2</span> coinfected pregnant women in Kenya who were not eligible to receive ART, patients received <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> 500 mg twice daily or placebo from 34 weeks gestation to 12 months post-partum. Among those receiving valacyclovir, the adjusted mean CD4 count was significantly higher (638 verus 565 <span class=\"nowrap\">cells/microL),</span> and the HIV RNA level was 0.4 log10 <span class=\"nowrap\">copies/ml</span> lower, at the 12 month follow-up visit [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/71\" class=\"abstract_t\">71</a>]. In addition, breast milk HIV RNA was significantly reduced at 6 and 14 weeks postpartum among those who received valacyclovir [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/72\" class=\"abstract_t\">72</a>].</p><p>In the Partners in Prevention trial discussed above, the primary aim was to determine whether <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> was associated with a reduced risk of HIV transmission. After the trial was underway, the investigators added an analysis to evaluate the effect of acyclovir on HIV disease progression among those patients who were not yet ART eligible [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/40\" class=\"abstract_t\">40</a>]. HIV disease progression was defined by a primary composite endpoint of: a) first occurrence of a CD4 count &lt;200 <span class=\"nowrap\">cells/microL,</span> b) initiation of ART, or c) non-trauma related death. At baseline, the median CD4 count was 462 <span class=\"nowrap\">cells/microL</span> and the median HIV-1 plasma RNA was 4.1 log<sub>10</sub> copies per microL. The following findings were observed: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A total of 608 patients reached the primary composite endpoint; patients in the intervention arm had a 16 percent risk reduction of HIV disease progression compared with placebo (HR 0.84, 95% CI 0.71-0.98). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A subgroup analysis among those with a CD4 count of &gt;350 <span class=\"nowrap\">cells/microL</span> also showed a clinical benefit in the patients on the <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> arm. This threshold was analyzed because the World Health Organization (WHO) had changed the indication to start ART to a CD4 count of &lt;350 <span class=\"nowrap\">cells/microL</span> during the course of the trial.</p><p/><p>More studies are needed to define the potential benefit of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> in the <span class=\"nowrap\">HIV/HSV-2-coinfected</span> patient who does not meet ART treatment criteria in resource-limited settings [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/73\" class=\"abstract_t\">73</a>]. However, combination ART, although more costly than acyclovir therapy, would be expected to have a more significant impact on overall HIV disease progression than HSV suppressive therapy. Finally, ART also decreases the risk of HIV transmission, whereas HSV prophylaxis does not [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/39\" class=\"abstract_t\">39</a>]. (See <a href=\"topic.htm?path=the-impact-of-antiretroviral-therapy-on-morbidity-and-mortality-of-hiv-infection-in-resource-limited-settings\" class=\"medical medical_review\">&quot;The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings&quot;</a> and <a href=\"topic.htm?path=hiv-infection-risk-factors-and-prevention-strategies\" class=\"medical medical_review\">&quot;HIV infection: Risk factors and prevention strategies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H108466581\"><span class=\"h2\">Individuals receiving antiretroviral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HSV-2 infection does not appear to be associated with increased markers of systemic inflammation or immune activation in patients with <span class=\"nowrap\">HIV/HSV-2</span> coinfection receiving ART. As an example, A cohort of 84 <span class=\"nowrap\">HIV/HSV-2</span> coinfected persons receiving antiretroviral therapy (ART) were followed for six months; HSV-2 infection was not associated with increased markers of systemic inflammation or immune activation [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/74\" class=\"abstract_t\">74</a>]. (See <a href=\"topic.htm?path=pathogenesis-and-biomarkers-of-cardiovascular-disease-in-hiv-infected-patients#H1593221\" class=\"medical medical_review\">&quot;Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients&quot;, section on 'Inflammation'</a>.) </p><p>In addition, treatment of HSV-2 with <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> does not provide any additional immunologic or virologic benefit. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a randomized trial of 99 HIV-infected persons on ART with asymptomatic HSV-2 infection, suppressive therapy with <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (1 gm daily) did not affect the CD4 cell count or the proportion of patients who had HIV viral load suppression [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/75\" class=\"abstract_t\">75</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a randomized trial of 60 <span class=\"nowrap\">HIV/HSV-2</span> coinfected adults with HIV suppression on ART, levels of systemic inflammation and immune activation (eg, the proportion of activated CD8+ T cells, levels of C-reactive protein, IL-6, and ICAM-1) were similar in those who received placebo, high dose <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (1 gm twice daily), and low dose valacyclovir (500 mg twice daily) [<a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/76\" class=\"abstract_t\">76</a>].</p><p/><p class=\"headingAnchor\" id=\"H875903124\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Opportunistic infections in HIV-infected adults and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4510276\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Herpes simplex virus type 2 infection is highly prevalent among HIV-infected patients. Whether this association results from similar modes of acquisition or to biologic interactions between the two viruses has been a topic of debate. (See <a href=\"#H4510284\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epidemiologic studies suggest that incident and prevalent genital herpes simplex virus type 2 (HSV-2) increases the risk of HIV acquisition. (See <a href=\"#H346164\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HSV-2 infection may contribute to risk of HIV acquisition through disruption of genital mucosal barriers or alteration of local immunologic factors or both.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HSV-2 infection may contribute to risk of HIV transmission by increasing HIV genital shedding in men and women, particularly at sites of HSV-2 genital ulcers. (See <a href=\"#H346171\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HSV-2-related genital ulcer disease is associated with increased levels of HIV plasma viremia among HIV-1 chronically-infected patients compared with patients with HIV infection alone. (See <a href=\"#H2189567\" class=\"local\">'Impact of HSV-2 on plasma HIV RNA'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical trials have shown that antiviral therapy for chronic suppression of genital HSV-2 infection is associated with a reduced level of HIV viremia. (See <a href=\"#H275545\" class=\"local\">'Effect of HSV treatment on HIV replication'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical trial data in diverse patient populations in both resource-rich and resource-limited settings do not support a role for HSV-2 suppressive therapy in preventing HIV acquisition among HSV-2 seropositive HIV-uninfected patients. (See <a href=\"#H5754473\" class=\"local\">'HSV therapy and HIV acquisition'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Despite epidemiologic and biologic evidence for an association between HSV-2 infection and HIV infection, clinical trials of HSV-2 suppressive therapy have not demonstrated protection against HIV transmission among HIV discordant couples in Africa in which the potential source partner received daily anti-HSV therapy. (See <a href=\"#H2540913\" class=\"local\">'HSV suppression and risk of HIV transmission'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suppressive antiviral therapy for HSV-2 infection may be associated with lower rates of HIV disease progression among HIV-infected patients not receiving antiretroviral therapy. This includes those with CD4 counts &lt;350 <span class=\"nowrap\">cells/microL</span> and postpartum women. In persons with CD4 counts &gt;400 <span class=\"nowrap\">cells/microL,</span> HSV-2 suppressive therapy was not associated with delayed CD4 cell decline. (See <a href=\"#H2541616\" class=\"local\">'HSV-2 antiviral therapy and HIV progression'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In <span class=\"nowrap\">HIV/HSV-2</span> coinfected persons receiving antiretroviral therapy, suppressive anti-herpesvirus therapy does not affect CD4 cell count, HIV suppression, or markers of inflammation. (See <a href=\"#H108466581\" class=\"local\">'Individuals receiving antiretroviral therapy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/1\" class=\"nounderline abstract_t\">Weiss HA, Buv&eacute; A, Robinson NJ, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS 2001; 15 Suppl 4:S97.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/2\" class=\"nounderline abstract_t\">Auvert B, Buv&eacute; A, Ferry B, et al. Ecological and individual level analysis of risk factors for HIV infection in four urban populations in sub-Saharan Africa with different levels of HIV infection. AIDS 2001; 15 Suppl 4:S15.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/3\" class=\"nounderline abstract_t\">Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/4\" class=\"nounderline abstract_t\">Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/5\" class=\"nounderline abstract_t\">Baeten JM, Benki S, Chohan V, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007; 21:1771.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/6\" class=\"nounderline abstract_t\">Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008; 3:e2230.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/7\" class=\"nounderline abstract_t\">Ramjee G, Williams B, Gouws E, et al. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr 2005; 39:333.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/8\" class=\"nounderline abstract_t\">Kapiga SH, Sam NE, Bang H, et al. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis 2007; 195:1260.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/9\" class=\"nounderline abstract_t\">del Mar Pujades Rodr&iacute;guez M, Obasi A, Mosha F, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS 2002; 16:451.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/10\" class=\"nounderline abstract_t\">Tobian AA, Ssempijja V, Kigozi G, et al. Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS 2009; 23:1589.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/11\" class=\"nounderline abstract_t\">Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003; 187:1513.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/12\" class=\"nounderline abstract_t\">Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009; 199:958.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/13\" class=\"nounderline abstract_t\">Brown JM, Wald A, Hubbard A, et al. Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007; 21:1515.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/14\" class=\"nounderline abstract_t\">Sanchez J, Lama JR, Peinado J, et al. High HIV and ulcerative sexually transmitted infection incidence estimates among men who have sex with men in Peru: awaiting for an effective preventive intervention. J Acquir Immune Defic Syndr 2009; 51 Suppl 1:S47.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/15\" class=\"nounderline abstract_t\">Looker KJ, Elmes JAR, Gottlieb SL, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis 2017; 17:1303.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/16\" class=\"nounderline abstract_t\">Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121:847.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/17\" class=\"nounderline abstract_t\">Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/18\" class=\"nounderline abstract_t\">Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/19\" class=\"nounderline abstract_t\">Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on July 10, 2017).</li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/21\" class=\"nounderline abstract_t\">Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/22\" class=\"nounderline abstract_t\">Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007; 21:589.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/23\" class=\"nounderline abstract_t\">Johnson KE, Redd AD, Quinn TC, et al. Effects of HIV-1 and herpes simplex virus type 2 infection on lymphocyte and dendritic cell density in adult foreskins from Rakai, Uganda. J Infect Dis 2011; 203:602.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/24\" class=\"nounderline abstract_t\">Albrecht MA, DeLuca NA, Byrn RA, et al. The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol 1989; 63:1861.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/25\" class=\"nounderline abstract_t\">Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/26\" class=\"nounderline abstract_t\">Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/27\" class=\"nounderline abstract_t\">Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008; 198:241.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/28\" class=\"nounderline abstract_t\">Baeten JM, McClelland RS, Corey L, et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 2004; 189:1466.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/29\" class=\"nounderline abstract_t\">Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/30\" class=\"nounderline abstract_t\">Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/31\" class=\"nounderline abstract_t\">Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/32\" class=\"nounderline abstract_t\">Nagot N, Ou&eacute;draogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/33\" class=\"nounderline abstract_t\">Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/34\" class=\"nounderline abstract_t\">Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49:77.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/35\" class=\"nounderline abstract_t\">Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/36\" class=\"nounderline abstract_t\">Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20:2305.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/37\" class=\"nounderline abstract_t\">Zuckerman RA, Lucchetti A, Whittington WL, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS 2009; 23:479.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/38\" class=\"nounderline abstract_t\">Kim HN, Wang J, Hughes J, et al. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J Infect Dis 2010; 202:734.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/39\" class=\"nounderline abstract_t\">Ludema C, Cole SR, Poole C, et al. Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS 2011; 25:1265.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/40\" class=\"nounderline abstract_t\">Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375:824.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/41\" class=\"nounderline abstract_t\">Mugwanya K, Baeten JM, Mugo NR, et al. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis 2011; 204:1912.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/42\" class=\"nounderline abstract_t\">Perti T, Saracino M, Baeten JM, et al. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. J Acquir Immune Defic Syndr 2013; 63:201.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/43\" class=\"nounderline abstract_t\">Vanpouille C, Lisco A, Introini A, et al. Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin. Antimicrob Agents Chemother 2012; 56:2604.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/44\" class=\"nounderline abstract_t\">McMahon MA, Siliciano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008; 283:31289.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/45\" class=\"nounderline abstract_t\">Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008; 4:260.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/46\" class=\"nounderline abstract_t\">LeGoff J, Tanton C, Delaugerre C, et al. No selection of nucleoside reverse transcriptase inhibitor resistance associated mutations by acyclovir suppressive therapy in herpes simplex virus-2/HIV-1 dually infected persons. AIDS 2010; 24:2595.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/47\" class=\"nounderline abstract_t\">Baeten JM, Lingappa J, Beck I, et al. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J Infect Dis 2011; 203:117.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/48\" class=\"nounderline abstract_t\">Cowan FM, Pascoe SJ, Barlow KL, et al. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008; 84:548.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/49\" class=\"nounderline abstract_t\">Paz-Bailey G, Sternberg M, Puren AJ, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. J Infect Dis 2009; 200:1039.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/50\" class=\"nounderline abstract_t\">Mayaud P, Legoff J, Weiss HA, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis 2009; 200:216.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/51\" class=\"nounderline abstract_t\">Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176:766.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/52\" class=\"nounderline abstract_t\">Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/53\" class=\"nounderline abstract_t\">Gray RH, Li X, Wawer MJ, et al. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004; 189:1209.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/54\" class=\"nounderline abstract_t\">Cachay ER, Frost SD, Richman DD, et al. Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection. J Infect Dis 2007; 195:1270.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/55\" class=\"nounderline abstract_t\">Barbour JD, Sauer MM, Sharp ER, et al. HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts. PLoS One 2007; 2:e1080.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/56\" class=\"nounderline abstract_t\">Golden MP, Kim S, Hammer SM, et al. Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 1992; 166:494.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/57\" class=\"nounderline abstract_t\">Chapman CJ, Harris JD, Collins MK, Latchman DS. A recombinant HIV provirus is synergistically activated by the HIV Tat protein and the HSV IE1 protein but not by the HSV IE3 protein. AIDS 1991; 5:945.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/58\" class=\"nounderline abstract_t\">Margolis DM, Rabson AB, Straus SE, Ostrove JM. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992; 186:788.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/59\" class=\"nounderline abstract_t\">Mosca JD, Bednarik DP, Raj NB, et al. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci U S A 1987; 84:7408.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/60\" class=\"nounderline abstract_t\">Diaz JJ, Dodon MD, Schaerer-Uthurralt N, et al. Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein. Nature 1996; 379:273.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/61\" class=\"nounderline abstract_t\">Margolis DM, Ostrove JM, Straus SE. HSV-1 activation of HIV-1 transcription is augmented by a cellular protein that binds near the initiator element. Virology 1993; 192:370.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/62\" class=\"nounderline abstract_t\">Koelle DM, Posavad CM, Barnum GR, et al. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998; 101:1500.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/63\" class=\"nounderline abstract_t\">Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007; 204:595.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/64\" class=\"nounderline abstract_t\">Sheth PM, Sunderji S, Shin LY, et al. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis 2008; 197:1394.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/65\" class=\"nounderline abstract_t\">Van de Perre P, Segondy M, Foulongne V, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008; 8:490.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/66\" class=\"nounderline abstract_t\">Hoots BE, Hudgens MG, Cole SR, et al. Lack of association of herpes simplex virus type 2 seropositivity with the progression of HIV infection in the HERS cohort. Am J Epidemiol 2011; 173:837.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/67\" class=\"nounderline abstract_t\">Aumakhan B, Gaydos CA, Quinn TC, et al. Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010; 5:e9973.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/68\" class=\"nounderline abstract_t\">Tan DH, Raboud JM, Kaul R, et al. Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. Clin Infect Dis 2013; 57:448.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/69\" class=\"nounderline abstract_t\">Ioannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178:349.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/70\" class=\"nounderline abstract_t\">Reynolds SJ, Makumbi F, Newell K, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis 2012; 12:441.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/71\" class=\"nounderline abstract_t\">Roxby AC, Drake AL, Ongecha-Owuor F, et al. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. PLoS One 2012; 7:e38622.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/72\" class=\"nounderline abstract_t\">Drake AL, Roxby AC, Ongecha-Owuor F, et al. Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial. J Infect Dis 2012; 205:366.</a></li><li class=\"breakAll\">http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (Accessed on September 27, 2010). (Accessed on September 09, 2011).</li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/74\" class=\"nounderline abstract_t\">Tan DH, Raboud JM, Szadkowski L, et al. Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV. AIDS Res Hum Retroviruses 2015; 31:276.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/75\" class=\"nounderline abstract_t\">Van Wagoner N, Geisler WM, Bachmann LH, Hook EW. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2. Int J STD AIDS 2015; 26:574.</a></li><li><a href=\"https://www.uptodate.com/contents/effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention/abstract/76\" class=\"nounderline abstract_t\">Yi TJ, Walmsley S, Szadkowski L, et al. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis 2013; 57:1331.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 14014 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H4510276\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H4510284\" id=\"outline-link-H4510284\">INTRODUCTION</a></li><li><a href=\"#H346164\" id=\"outline-link-H346164\">EPIDEMIOLOGY</a><ul><li><a href=\"#H2188350\" id=\"outline-link-H2188350\">HIV acquisition</a><ul><li><a href=\"#H346025\" id=\"outline-link-H346025\">- Prevalent HSV-2 infection</a></li><li><a href=\"#H4510298\" id=\"outline-link-H4510298\">- Incident HSV-2 infection</a></li></ul></li><li><a href=\"#H2188381\" id=\"outline-link-H2188381\">HIV transmission</a><ul><li><a href=\"#H2188414\" id=\"outline-link-H2188414\">- Discordant couples</a></li></ul></li></ul></li><li><a href=\"#H346171\" id=\"outline-link-H346171\">PATHOGENESIS</a><ul><li><a href=\"#H346053\" id=\"outline-link-H346053\">Disruption of mucous membranes</a></li><li><a href=\"#H346082\" id=\"outline-link-H346082\">Local immunologic factors</a></li><li><a href=\"#H2188488\" id=\"outline-link-H2188488\">HIV RNA shedding in HSV genital lesions</a></li></ul></li><li><a href=\"#H5754473\" id=\"outline-link-H5754473\">HSV THERAPY AND HIV ACQUISITION</a></li><li><a href=\"#H347552\" id=\"outline-link-H347552\">HSV THERAPY AND HIV TRANSMISSION</a><ul><li><a href=\"#H275545\" id=\"outline-link-H275545\">Effect of HSV treatment on HIV replication</a></li><li><a href=\"#H2190093\" id=\"outline-link-H2190093\">Effect of HSV therapy on HIV genital shedding</a></li><li><a href=\"#H2540913\" id=\"outline-link-H2540913\">HSV suppression and risk of HIV transmission</a></li></ul></li><li><a href=\"#H2189330\" id=\"outline-link-H2189330\">THE IMPACT OF HSV-2 INFECTION ON HIV DISEASE</a><ul><li><a href=\"#H2189567\" id=\"outline-link-H2189567\">Impact of HSV-2 on plasma HIV RNA</a><ul><li><a href=\"#H2189594\" id=\"outline-link-H2189594\">- Mechanisms of enhanced HIV replication</a></li></ul></li><li><a href=\"#H2189227\" id=\"outline-link-H2189227\">Impact of HSV-2 on T cell decline and recovery</a></li><li><a href=\"#H2541616\" id=\"outline-link-H2541616\">HSV-2 antiviral therapy and HIV progression</a></li><li><a href=\"#H347860494\" id=\"outline-link-H347860494\">Individuals not receiving antiretroviral therapy</a></li><li><a href=\"#H108466581\" id=\"outline-link-H108466581\">Individuals receiving antiretroviral therapy</a></li></ul></li><li><a href=\"#H875903124\" id=\"outline-link-H875903124\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H4510276\" id=\"outline-link-H4510276\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hiv-infection-risk-factors-and-prevention-strategies\" class=\"medical medical_review\">HIV infection: Risk factors and prevention strategies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-and-biomarkers-of-cardiovascular-disease-in-hiv-infected-patients\" class=\"medical medical_review\">Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: Opportunistic infections in HIV-infected adults and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-impact-of-antiretroviral-therapy-on-morbidity-and-mortality-of-hiv-infection-in-resource-limited-settings\" class=\"medical medical_review\">The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-type-2-in-hiv-infected-patients\" class=\"medical medical_review\">Treatment of genital herpes simplex virus type 2 in HIV-infected patients</a></li></ul></div></div>","javascript":null}